The American Medical Association (AMA) has granted a CPT® Proprietary Laboratory Analyses (PLA) Code for Renayltix AI’s lead product, KidneyIntelX. The new code, 0105U, has been approved and published by the AMA CPT Editorial Panel, and is scheduled to become effective on October 1, 2019.Medicare Price for New CPT CodeA payment rate for the new code will be established for Medicare patients through the 2019 Clinical Lab Fee Schedule (CLFS) Annual Public Meeting process. Renayltix AI will shortly
Read More
Biomarkers| Big Data| News, Analysis, Insights - HIT Consultant
Can Artifical Intelligence Solve The Chronic Kidney Disease Epidemic?
Chronic kidney disease (CKD) is a growing epidemic worldwide. Currently, there are 850 million individuals suffering from CKD globally, with 40 million in the United States alone. Of these individuals, 96 percent are not aware of having CKD, as kidney disease often exhibits no symptoms until it has progressed to a late stage.
As this epidemic continues to grow, healthcare providers and organizations are working to determine how artificial intelligence (AI) can be used to analyze electronic
Read More
Washington University Alzheimer’s Study Adopts BYOD Technology for Clinical Trials & Observational Study
The Washington University School of Medicine in Saint Louis has selected Datacubed Health’s mobile platform has been selected to support worldwide studies for those at risk of Dominantly Inherited Alzheimer’s Disease, a rare form of early-onset Alzheimer’s Disease. The Linkt platform enables the collection of real-time data on sleep, diet and other biomarkers using a “bring your own device” (BYOD) study model.Datacubed Health’s app, platform and web-based portal will be used by scientists at the
Read More
Study: Fitbit Devices Could Predict Inflammatory Bowel Disease (IBD) Flare-Ups
Fitbit devices could help predict the flare-ups of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, according to a new study published in the Journal of Crohn's and Colitis. The year-long study, which was recently presented at Digestive Disease Week, was conducted by the University of Chicago.Impact of IBD Flare-UpsEven when managed well, IBD can flare up or cause symptoms unexpectedly, which may be triggered by diet, stress, and physical activity (or lack
Read More
Altoida Raises $6.3M for Early Detection of Alzheimer’s Using AI & Augmented Reality
Altoida Inc., a digital health company using digital
biomarkers to drive better clinical outcomes for brain diseases has raised
$6.3M in Series A funding led by M Ventures, the corporate venture capital arm
of the science and technology company Merck KGaA, Darmstadt, Germany. The round
also includes participation from Grey Sky Venture Partners, VI Partners AG,
Alpana Ventures, and FYRFLY Venture Partners.
Taking Aim at the Alzheimer’s Disease Epidemic
The number of people living with
Read More
Canadian Government Awards $49M Grant to Establish Canada-wide AI Health Data Platform
The government of Canada has announced an investment grant of up to $49 million in the Digital Health and Discovery Platform (DHDP), a network of partners that seeks to establish a cutting-edge Canada-wide health data platform. Through this new platform, researchers and doctors will work to accelerate the development of new and personalized treatments to help to find cures for diseases that affect Canadians. While the platform will initially focus on cancer, the plan is to expand to other areas
Read More
FDA Grants Breakthrough Designation to RenalytixAI for AI-Enabled Diagnostic for Kidney Disease
RenalytixAI, a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, today announced that it has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA), for its lead diagnostic, KidneyIntelX™. This is the first such designation for an AI-enabled diagnostic for kidney disease publicly announced by any company.FDA Breakthrough Devices Program OverviewThe FDA’s Breakthrough Devices Program is a voluntary program for certain
Read More
Sonde Health Nabs $16M to Commercialize Vocal Biomarker Device to Diagnose Diseases
Sonde Health, a Boston-based digital medicine company developing a vocal biomarker device to transform the way we monitor and diagnose our mental and physical health has raised $16 million in Series A funding. The round was led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany), with participation from MP Healthcare Venture Management, Inc. (the corporate venture capital arm of Mitsubishi Tanabe Pharma Corporation), Neoteny 4, LP, Canepa Healthcare, and founder
Read More
Amazon Alexa Is Now HIPAA-Eligible, What’s Next for Healthcare?
Big News, But Just The Beginning
These days, big news stories in healthcare are just as likely to come from large technology companies as from major healthcare institutions. Case in point: In early 2018, Amazon created a huge stir in the industry early by announcing a venture with JPMorgan and Berkshire Hathaway that promised to go after the “hungry tapeworm” that is the cost of healthcare in the
Read More
Mayo Clinic to Develop New Diagnostic Test Using Patients’ Breath to Detect Lung Cancer
Mayo Clinic Laboratories is teaming up with Breath Diagnostics to develop new clinical diagnostic tests that use patient breath samples to identify individual biomarkers that can predict a spectrum of diseases. The first collaboration will focus on a diagnostic test that detects lung cancer using patients' exhaled breath. Benefits of BiomarkersBiomarkers are measurable substances that help in predicting the severity of a disease or infection. Examples of a biomarker include an individual's pulse
Read More
